Page last updated: 2024-11-06

flumecinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

flumecinol: liver microsomal drug metabolizing enzyme inducer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID41870
CHEMBL ID2107440
CHEBI ID135160
SCHEMBL ID667363
MeSH IDM0067263

Synonyms (53)

Synonym
AKOS012083421
rgh-3332
zixoryn
flumecinol
zyxorin
benzhydrol, alpha-ethyl-3-(trifluoromethyl)-
benzenemethanol, alpha-ethyl-alpha-phenyl-3-(trifluoromethyl)-
flumecinol [inn]
3-trifluoromethyl-alpha-ethylbenzhydrol
flumecinolum [inn-latin]
einecs 260-176-1
alpha-ethyl-alpha-phenyl-3-(trifluoromethyl)-benzenemethanol
alpha-ethyl-3-(trifluoromethyl)benzhydrol
brn 2138833
CHEBI:135160
1-phenyl-1-[3-(trifluoromethyl)phenyl]propan-1-ol
jb0ya8ldow ,
56430-99-0
flumecinolum
unii-jb0ya8ldow
CHEMBL2107440
flumecinol [mi]
benzenemethanol, .alpha.-ethyl-.alpha.-phenyl-3-(trifluoromethyl)-
flumecinol [mart.]
flumecinol [who-dd]
(+/-)-flumecinol
1-(3-trifluoromethylphenyl)-1-phenylpropan-1-ol
3-(trifluoromethyl)-.alpha.-ethylbenzhydrol
113755-17-2
.alpha.-ethyl-3-(trifluoromethyl)benzhydrol
SCHEMBL667363
3-trifluoromethyl-alpha-ethyl-benzhydrol
ethyl phenyl 3-trifluoromethylphenyl carbinol
mfcd00867388
m-trifluoromethyl-alpha-ethylbenzhydrol
Z1020762628
1-phenyl-1-(3-(trifluoromethyl)phenyl)propan-1-ol
Q27281410
flumecinol, (-)-
FMZ2L5L8WH ,
benzenemethanol, .alpha.-ethyl-.alpha.-phenyl-3-(trifluoromethyl)-, (+)-
VWK2338NBP ,
benzenemethanol, .alpha.-ethyl-.alpha.-phenyl-3-(trifluoromethyl)-, (-)-
flumecinol, (+)-
(+)-flumecinol
107317-30-6
107317-31-7
benzenemethanol, alpha-ethyl-alpha-phenyl-3-(trifluoromethyl)-, (+)-
unii-fmz2l5l8wh
benzenemethanol, alpha-ethyl-alpha-phenyl-3-(trifluoromethyl)-, (-)-
unii-vwk2338nbp
DTXSID80866560
EN300-253142

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It reports data of evaluation of HMO activity in pediatric and adult cancer patients, which has shown a decrease in HMO activity in one third of patients without clinical signs of hepatopathy and two thirds of those with toxic hepatic damages after prior chemotherapy."( [The drop in toxicity and the rise in the effectiveness of antineoplastic chemotherapy by correcting the activity of liver monooxygenases: from the experiment to the clinical practice].
Bogush, EA; Bogush, TA; Durnov, LA; Syrkin, AB, 2002
)
0.31

Pharmacokinetics

The peak concentration of unchanged flumecinol in the plasma (130) was determined by computer evaluation of the plasma concentration-time curves.

ExcerptReferenceRelevance
" The peak concentration of unchanged flumecinol in the plasma (130."( Pharmacokinetic studies of [14C]-flumecinol in humans.
Csetényi, J; Kerpel-Fronius, S; Klebovich, I; Vereczkey, L, 1987
)
0.83
" The pharmacokinetic parameters of flumecinol were determined by computer evaluation of the plasma concentration-time curves."( Pharmacokinetic studies of flumecinol in man and dog.
Bodrogligeti, I; Kerpel-Fronius, S; Klebovich, I; Ringwald, G; Vereczkey, L, 1982
)
0.84

Compound-Compound Interactions

ExcerptReferenceRelevance
" Administration of nicotinamide in combination with ziksorin or phenobarbital enhanced the enzyme-inducing effects of the latter."( [Effect of nicotinic acid, nicotinamide and its combination with ziksorin and phenobarbital on the UDP glucuronyl transferase activity of the hepatic endoplasmic reticulum in the rat].
Bushma, MI; Legon'kova, LF; Lukienko, PI,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" This dosage also induces the first and the second phases of reactions."( Human tolerance of flumecinol (Zixoryn, RGH-3332), its regime and dosage in healthy volunteers.
Ferenci, J; Horvath, T; Jávor, T; Nagy, L; Past, T; Radnai, B; Vezekenyi, Z, 1983
)
0.59
" The action of a single orally administered dosage of 40 ml/kg was analysed."( Hormonal environment and age influencing the activity of flumecinol, a synthetic enzyme inducer.
Kulcsár, A; Kulsár-Gergely, J, 1981
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (73.08)18.7374
1990's9 (17.31)18.2507
2000's4 (7.69)29.6817
2010's0 (0.00)24.3611
2020's1 (1.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.31 (24.57)
Research Supply Index4.33 (2.92)
Research Growth Index4.05 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (7.14%)5.53%
Reviews5 (7.14%)6.00%
Case Studies3 (4.29%)4.05%
Observational0 (0.00%)0.25%
Other57 (81.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]